Valacyclovir decreases plasma HIV-1 RNA in HSV-2 seronegative individuals: A randomized placebo-controlled crossover trial

Clinical Infectious Diseases

Volumn 60, Issue 11, 2015, Pages 1708-1714

  Vanpouille, Christophe ^a   Lisco, Andrea ^a   Grivel, Jean Charles ^a   Bassit, Leda C ^b   Kauffman, Robert C ^b   Sanchez, Jorge ^c   Schinazi, Raymond F ^b   Lederman, Michael M ^d   Rodriguez, Benigno ^d   Margolis, Leonid ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b EMORY CENTER FOR AIDS RESEARCH   (United States)

^c ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acyclovir; herpesvirus; HIV 1; HSV 2; reverse transcriptase inhibitor

Indexed keywords

ACICLOVIR; PLACEBO; VALACICLOVIR; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VALINE;

ACUTE HEPATITIS B; ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA CONTENT; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GENE DOSAGE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VIVO STUDY; LIMIT OF DETECTION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERODIAGNOSIS; SEROPREVALENCE; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PLASMA; VIROLOGY; YOUNG ADULT;

ACYCLOVIR; ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PLACEBOS; PLASMA; RNA, VIRAL; VALINE; VIRAL LOAD; VIRUS REPLICATION; YOUNG ADULT;

EID: 84930395995     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ172     Document Type: Article

References (40)

1. Elion GB. The biochemistry and mechanism of action of acyclovir. B Antimicrob Chemother 1983; 12(suppl B):9-17.
2. Patil SD, Koga M, Schneller SW, Snoeck R, De Clercq E. (+-)- carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties. J Med Chem 1992; 35:2191-5.
3. Jeong LS, Yoo SJ. Synthesis and antiviral activity of novel isodideoxy nucleosides with exocyclic methylene. Bioorg Med Chem Lett 1998; 8:847-52.
4. Balzarini J, Haller-Meier F, De Clercq E, Meier C. Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir. Antivir Chem Chemother 2001; 12:301-6.
5. Mitsuya H, Broder S. Strategies for antiviral therapy in AIDS. Nature 1987; 325:773-8.
6. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349-59.
7. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305-13.
8. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. [see comment]. B Engl J Med 2007; 356:790-9.
9. Zuckerman RA, Lucchetti A, Whittington WL, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500-8.
10. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)- suppressive therapy decreases plasma and genital HIV-1 levels in HSV- 2/HIV-1 coinfected women: a randomized, placebo-controlled, crossover trial. J Infect Dis 2008; 198:1804-8.
11. Dunne EF, Whitehead S, Sternberg M, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77-83.
12. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461-9.
13. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-39.
14. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010; 375:824-33.
15. Tanton C, Weiss HA, Rusizoka M, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial. J Infect Dis 2010; 201:1285-97.
16. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. B-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis 2011; 204:1912-7.
17. Drake AL, Roxby AC, Ongecha-Owuor F, et al. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial. J Infect Dis 2012; 205:366-75.
18. Roxby AC, Drake AL, Ongecha-Owuor F, et al. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. PloS One 2012; 7:e38622.
19. Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo- controlled trial. Lancet Infect Dis 2012; 12:441-8.
20. Perti T, Saracino M, Baeten JM, et al. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. J Acquir Immune Defic Syndr 2013; 63:201-8.
21. Van de Perre P, Segondy M, Foulongne V, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis 2008; 8:490-7.
22. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.[see comment]. Cell Host & Microbe 2008; 4:260-70.
23. McMahon MA, Siliciano JD, Lai J, et al. The anti-herpetic drug acyclovir inhibits HIV replication and selects the V75i reverse transcriptase multi-drug resistance mutation. J Biol Chem 2008; 283:31289-93.
24. McMahon MA, Parsons TL, Shen L, Siliciano JD, Siliciano RF. Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. J Virol 2011; 85:4618-22.
25. Jones B, Kenward MG. Design and analysis of cross-over trials. 2nd ed. B & Hall/CRC monographs on statistics & applied probability, 2003.
26. Senn S. Cross-Over Trials in Clinical Research. In: Chichester JWaS, 2002:35-88.
27. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8:7-20.
28. Tchesnokov EP, Obikhod A, Massud I, et al. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. B Biol Chem 2009; 284:21496-504.
29. McMahon MA, Siliciano JD, Kohli RM, Siliciano RF. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 2010; 24:319-23.
30. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.[see comment]. B Engl J Med 2008; 358:1560-71.
31. Ludema C, Cole SR, Poole C, Chu H, Eron JJ.Meta-analysis of randomized trials on the association of prophylactic acyclovir and HIV-1 viral load in individuals coinfected with herpes simplex virus-2. AIDS 2011; 25:1265-9.
32. Katzenstein DA, Hughes M, Albrecht M, et al. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. AIDS Res Hum Retroviruses 2000; 16:1031-7.
33. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. B-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:203-8.
34. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179-85.
35. Lingappa JR, Hughes JP, Wang RS, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. B One 2010; 5:e12598.
36. Yi TJ, Walmsley S, Szadkowski L, et al. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis 2013; 57:1331-8.
37. Roxby AC, Liu AY, Drake AL, et al. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir. AIDS Res Hum Retroviruses 2013; 29:94-8.
38. Kim HN, Wang J, Hughes J, et al. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis 2010; 202:734-8.
39. LeGoff J, Tanton C, Delaugerre C, et al. No selection of nucleoside reverse transcriptase inhibitor resistance associated mutations by acyclovir suppressive therapy in herpes simplex virus-2/HIV-1 dually infected persons. AIDS 2010; 24:2595-6.
40. Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J Infect Dis 2011; 203:117-21.